Mar 26, 2020
Citius Pharmaceuticals Announces Publication in Antimicrobial Agents and Chemotherapy Journal of Positive Preclinical Results for Mino-Lok® in Rapidly Eradicating Candida Auris
Dec 09, 2019
Stadius Biopharma to Present Data on Fully Human Antibodies for the Treatment of Candida Infections
Nov 14, 2019
SCYNEXIS Commends the CDC for the Recognition of Candida auris as a New "Urgent Threat" in its Updated Report on Antibiotic Resistance Threats in the United States
Nov 07, 2019
SCYNEXIS Reports Positive Top-Line Results from First Phase 3 Registration Study of Oral Ibrexafungerp in Vulvovaginal Candidiasis (VANISH-303)
Oct 02, 2019
SCYNEXIS to Present Data at IDWeek 2019 and the 9th Congress on Trends in Medical Mycology (TIMM-9) Highlighting Scientific and Clinical Evidence of Ibrexafungerp's Activity Against Resistant Fungal Pathogens, Including Candida auris
Sep 16, 2019
Amplyx Pharmaceuticals Announces Positive Preliminary Data from Ongoing Fosmanogepix Phase 2 Study in Candidemia
Jul 24, 2019
SCYNEXIS Announces Special Protocol Assessment (SPA) Agreement with FDA for Phase 3 Study Evaluating Oral Ibrexafungerp for the Prevention of Recurrent Vulvovaginal Candidiasis (VVC) (CANDLE Study)
Jul 10, 2019
New FDA-Cleared Microbicidal Liquid Kills Deadly, Drug-Resistant Candida Auris Superbug on Contact
May 13, 2019
Citius Pharmaceuticals' Mino-Lok® Highly Efficacious in Rapidly Eradicating Candida auris
Apr 22, 2019
Diagnostics Company Launches New Molecular Test to Identify Deadly Superbug, Candida auris.
Jan 31, 2019
Sosei Heptares to Launch ORAVI® Mucoadhesive Tablets 50mg for Oropharyngeal Candidiasis in Japan
Oct 23, 2018
BioGX Launches 5 new CE Mark IVD Tests, Expands Sexual Health Panels on the BD MAX(TM)
Oct 15, 2018
SCYNEXIS, Inc. Announces First Patient Dosed in Phase 3 Open-label Study Evaluating Oral Ibrexafungerp in Candida auris Infections (CARES)
Jun 11, 2018
SCYNEXIS Presents SCY-078 Data at ASM Microbe 2018
May 01, 2018
SCYNEXIS's Oral SCY-078 Receives FDA QIDP and Fast Track Designations for the Treatment of VVC and Prevention of Recurrent VVC
Apr 20, 2018
FDA authorizes new use of test, first to identify the emerging pathogen Candida auris
Apr 05, 2018
Published Research Shows Ceragenin CSA-131's Potent Efficacy against Candida auris, a New Serious Global Health Threat
Mar 20, 2018
SCYNEXIS Presents Data at Superbugs and Superdrugs 2018
Nov 07, 2017
SCYNEXIS Reports Third Quarter 2017 Financial Results and Provides Company Update
Aug 03, 2017
Candidiasis Therapeutics Pipeline Analysis, 2017 - Approximately 22 Active Drug Candidates in Different Stages of Development